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CHAPTER 8
S u m m a r y
The aim of the studies presented in this thesis was to explore and to exploi t  he tumor
cytotoxic potent ial  of  macrophages in immunotherapeut ic treatment of ovarian
cancer.  For this purpose, we performed in vivo studies with non-tumor-bearing mice
(chapters 3 and 4) as wel l  as with mice bearing a murine ovarian tumor (chapters 4
and 5).  In addit ion, in vi t ro studies with human ovarian tumor cei l  l ines and human
ovarian tumors were performed (chapters 6 and 7).
Chapter 2 encompasses a l i terature review concerning the involvement of
macrophages in tumor biology in general .  Macrophages, when act ivated by bacter ial
cel l  wal l  components or certain cytokines, are able to specif ical ly recognize and ki l l
tumor cel ls.  Among the mediators capable of direct cel l  k i l l ing are tumor-necrosis
factor (TNF) and ni tr ic oxide (NO). Macrophages populate areas both within and
around tumors, of ten in large numbers, indicat ing that these cel ls are recrui ted to
si tes of tumor growth. Tumor cel ls can secrete mediators that on the one hand attract
macrophages and on the other are able to suppress their  act iv i ty.  These seemingly
opposite observat ions i l lustrate our l imited knowledge of the role and funct ion of
tumor-associated macrophages. The state of act ivat ion of the macrophages (e.g
when macrophage are in a pr imed condit ion) probably determines to a large extent
whether macrophages are al lowed to lyse tumor cel ls by secret ing cytotoxic
mediators or rather st imulate tumor growth by secret ing mediators such as lL-10
which are involved in angiogenesis.  This process of blood vessel formation is
necessary for tumors to progress beyond a certain ini t ia l  stage. The ambiguous role
of macrophages in tumor development cal ls for an immunotherapeut ic treatment
aimed at macrophage act ivat ion. A number of c l in ical  phase I  and l l  t r ia ls based on
act ivated macrophages or subpopulat ions of macrophages ( i .e.  dendri t ic el ls)  have
already been performed, others are st i l l  ongoing. l t  should be noted, that al though this
kind of immunotherapy is expected to be benef ic ial  for pat ients with minimal residual
disease, only pat ients with advanced disease are enrol led in phase land l l  c l in ical
studies. At that late stage of the disease, inaccessibi l i ty of  the tumor by
macrophages, low macrophage to tumor cel l  rat io 's and immunosuppression f  the
pat ients are major obstacles for immunotherapy to be effect ive. This presumably
explains so far,  al though immune responses have been described, no complete
remission have been obtained in these cl in ical  studies.
Chapter 3 describes the effects concerning the cytotoxicity of peritoneal cells
upon intraperi toneal ( i .p.)  in ject ions of recombinant murine granulocyte-macrophage
colony-st imulat ing factor (rmGM-CSF) in non-tumor bearing mice. Upon i .p.  in ject ions
with rmGM-CSF the number of per i toneal cel ls increased. The increase in cel l
number was mainly accounted for by an increase in the number of macrophages.
The peritoneal cells were highly cytotoxic upon additional in vitro stimulatlon with
l ipopolysaccharide (LPS). This was in contrast with peri toneal cel ls isolated from
control mice treated with phosphate-buffered saline, that were only moderately
cytotoxic upon LPS stimulation in vitro. The cytotoxic capacity was strongly correlated
with the amount of NO secreted by these cel ls.  As the peri toneal cel ls consisted for
B0% of macrophages, the results obtained can presumably be attr ibuted to this cel l
populat ion. The results of this study indicate that i .p.  in ject ions with rmGM-CSF can
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cavity with a high cytotoxic potential.
In chapter 4 we describe the cytotoxic propert ies of per i toneal cel ls upon i .p.
inject ions of l iposomal muramyltr ipept ide phosphat idylethanolamine (L-MTP-PE) in
non-tumor bearing mice. Inject ions with L-MTP-PE caused a strong increase in the
number of per i toneal cel ls,  mainly due to an increase in the number of per i toneal
macrophages and to a minor extent due to an increase in the number of neutrophi ls.
These peritoneal cells were highly cytotoxic to tumor cells after in vitro stimulation
with LPS, in contrast o control  per i toneal cel ls.  Because placebo l iposomes also
rnduced a moderate increase in the number of per i toneal cel ls and cytotoxic potent ial
of  these cel ls,  we conclude that certain l ip id components in the l iposomes, such as
phosphat idylser ine, may by themselves inf luence the immune system. Secondly,  we
invest igated the effects of combined i .p.  t reatment with L-MTP-PE, GM-CSF and
cisplat in using drf ferent treatment schedules in mice bearing a murine ovarian tumor.
Despite the large numbers of per i toneal macrophages present in the peri toneal
cavi ty,  no prolonged survival  was observed with any of the treatment schedules
tested. Remarkable, however,  was the inhibi tory effect of  a large inject ion volume on
tumor growth. Mult ip le dai ly in ject ions with 0.5 ml of di luent within a few days after
tumor inoculat ion, strongly inhibi ted tumor growth. Taking these results together,  we
bel ieve that the tumor cel ls used in this murine ovarian tumor model are too rapidly-
growing to al low the observat ion of an ant i tumor effect result ing in a prolonged
survival  in these mice
In chapter 5 we describe a di f ferent approach to achieve an i .p.
immunotherapeut ic macrophage-mediated immunotherapeut ic treatment.  We
injected the rmGM-CSF gene, cloned into an expression vector based on the Semliki
Forest v irus (SFV) repl icon, i .p.  into mice. Thus, we expected to achieve prolonged
secretion of the recombinant protein over a period of several days. Initial results with
i .p.  in ject ions of SFV part ic les encoding for the luci ferase reporter gene, indicated
that transfect ion of cel ls af ter i .p.  in ject ions with SFV part ic les predominant ly occur in
the tumor cel ls in the peri toneal cavi ty of tumor-bearing animals and in the peri toneal
l in ing. This would mean that most rmGM-CSF produced by transfected cel ls can be
expected to be released into the peritoneal cavity. ln contrast to i.p. injections with
soluble rmGM-CSF, we observed that upon rn yiyo transfection with SFV-GM-CSF
particles the peritoneal cells were tumor cytotoxic without additional in vitro
st imulat ion with LPS. When tumor-bearing mice were treated with SFV-GM-CSF
part ic les i .p. ,  inhibi t ion of tumor growth was observed during the f i rst  12 days after
tumor inoculat ion. Nonetheless, the overal l  survival  of  the mice was not signi f icant ly
prolonged upon rn viyo transfection with the rmGM-CSF gene. Taken together, our
resul is indicate that i .p.  rnject ions with SFV-GM-CSF part ic les leads to rmGM-CSF
production by transfected cells in the peritoneal cavity. Transfection with virus
particles, can induce death of the transfected cells. This may, conceivably, give rise
to the product ion of cel l  debris which in turn may el ic i t  an immunological  response.
Thus, the presence of v irus part ic les may indirect ly be responsible for the induct ion of
an immune react ion which, together with rmGM-CSF secret ion by transfected cel ls,
might be responsible for the in vivo activation of peritoneal macrophages.
While the previous chapters describe the cytotoxic potential of murine peritoneal
macrophages, chapters 6 and 7 mainly focus on the potent ial  role of human
monocytes and macrophages in relat ion to human ovarian tumor cel ls and human
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ovarian cancer. In chapter 6 we investigated the potential of human monocytes to
lyse human ovarian tumor cel l  l ines. These cel l  l ines fol lowing transfect lon with
plasmids containing mutated p53 genes, expressed several  mutat ions in the p53
tumor suppressor gene, which is involved in apoptosis.  Due to the expression of
various mutant p53 proteins these cell l ines differed in their sensitivity to cytostatic
drugs and TNF. We showed that monocytes isolated from healthy volunteers were
able to eff ic ient ly lyse the tumor cel ls.  Cel l  k i l l ing could part ly be attr ibuted to TNF
and NO secretion. Also peritoneal macrophages isolated from rmGM-CSF and L-
MTP-PE treated mice were able to lyse tumor cells. Macrophages isolated from L-
MTP-PE treated mice were cytotoxic to tumor cells without additional in vitro
activation, in contrast to macrophages isolated from rmGM-CSF treated mice.
Apparently, L-MTP-PE is able to activate peritoneal macrophages directly to tumor
cytotoxicity. These results indicate that the mechanism of tumor cell lysis by activated
monocytes proceeds independent of the p53 apoptotic route. This leads us to
conclude that immunotherapeutic treatment based on monocyte/macrophage
activation may provide a cotreatment modality of ovarian tumors that have become
resistant to convent ional chemotheraoeut ics.
Final ly,  in chapter 7 we determined in an immunohistochemical study the
expression of two inducible nzymes in surgical ly obtained mater ial  of  human ovarian
tumors. Both enzymes have been described to be expressed in some tumors as well
as in activated macrophages. The inducible enzyme cyclo-oxygenase 2 (COX-2) is
responsible for the production of the macrophage suppressive mediator
prostaglandin E2 (PGE2), whi le the inducible type of NO-synthase ( iNOS) is
responsible for the production of NO. NO is one of the mediators directly involved in
cell kill ing but it can also function as a vasodilator. The latter function may therefore
provide a favorable condition in tumor development. We investigated the expression
of these enzymes in epithel ial  stroma of mal ignant,  borderl ine, and benign ovarian
tumors and in tumor-associated macrophages. Expression of COX-2 was observed
in the epithel ial  stroma of a major i ty of the mal ignant,  borderl ine as wel l  as benign
tumors, whi le in a minori ty of the tumors, iNOS expressioir  in the epithel ial  stroma
cells was found. Most tumors also contained macrophages. There was a correlation
between the grade of mal ignancy of the tumor and the number of macrophages
found in and around the tumor; the largest numbers of macrophages were
encountered in the malignant umors. Macrophages positive for COX-2 or |NOS were
only observed in some mal ignant and borderl ine tumors, but not in benign tumors.
The COX-2 and INOS positive macrophages represented only small subpopulations
of the total tumor-associated macrophage population. Taken together, our results
show that COX-Z expression is not l imited to mal ignant umors, but can also be
expressed in epithel ial  cel ls of  non-mal ignant tumors. Furtherrnore, only a smal l
populat ion of the tumor-associated macrophages in some mal ignant and borderl ine
tumors were positive for COX-2 or iNOS, indicating that most tumor-associated
macrophages were not in an activated state.
In conclusion, explor ing the potent ial  of  the peri toneal macrophage populat ion to
lyse peritoneal tumor cells we found that, although the peritoneal macrophage
population could be considerably expanded, and stimulated to tumor cytotoxicity, this
did not result  in a prolongat ion of survival  in the murine ovarian tumor model used in
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SUMMARY AND FUTURE PERSPECI/YES
administrat ion of the GM-CSF gene in a viral  vector and the observat ion that
macrophages and monocytes are able to lyse tumor cells irrespective of their p53
status provides useful information for the further develooment of new
immunotherapeut ic reatments of ovarian cancer.
Futu re  perspec  t i ves
The results presented in this study show that upon i .p.  t reatment with ei ther GM-CSF
and L-MTP-PE the number of per i toneal macrophages in mice increased signi f icant ly.
In addition, the tumor cyiotoxic capacity of these macrophages was increased
compared to that of control animals. Although peritoneal macrophages derived from
L-MTP-PE-treated animals were directly cytotoxic towards some tumor cell types,
peritoneal macrophages isolated from GM-CSF-treated mice always needed an
additional stimulation to become fully tumor cflotoxic. Therefore, an interesting
finding described in this thesis is the direct activation to tumor cytotoxicity of
peritoneal macrophages upon GM-CSF producing virus particles. This effect was not
observed upon inject ions with soluble GM-CSF, non-encoding virus part ic les or virus
particles encoding an irrelevant protein. We therefore hypothesize that in our
experiments the viral vector, used in the in vivo transfection with the GM-CSF gene,
by itself serves as a trigger for macrophage activation, additional to the GM-CSF
produced by the transfected cells. These results may have implications for gene
therapeutic strategies in cancer therapy, considering the ongoing debate on whether
non-viral or viral vectors should be used in gene therapeutic treatment. The
observat ion that a viral  vector by i tsel f  can induce an addit ional immune response,
indicates that the use of a viral vector may provide a favorable condition in gene
therapy that aims at the act ivat ion of the immune system.
Furthermore, in vitro experiments howed that cells of human ovarian tumor cell
l ines resistant to chemotherapeut ics, based on p53 mutat ions were eff lc ient ly ki l led
by human monocytes. These monocytes could be further activated to tumor
cytotoxicity with GM-CSF and/or LPS. Remarkably, as NO and TNF are considered
as the most important mediators in tumor cel l  k i l l ing, inhibi t ion of NO-synthesis in
monocytes and neutralization of TNF secreted by monocytes with anti-TNF
antibodies only resulted in a minor decrease in monocyte-mediated cel l  k i l l ing. These
results indicate, that also other pathways are operat ional in tumor cel l  lysis by
(human) monocytes. Over the past decade, new members of the TNF and TNF-
receptor family have been discovered among which are FasL/Fas and TRAIL/TRAIL-
receptor. Both pathways function via a ligand/receptor binding. Until now, their role in
monocyte/macrophage-mediated umor cytotoxicity has not yet been investigated.
Therefore it would be interesting to elucidate the potential role of these or other
unknov,rn mediators in cell kill ing by monocytes or macrophages.
Overall, our results show that macrophages or monocytes can have a supportive
role in immunotherapeutic treatment of ovarian cancer. A major problem to overcome
might be the recrui tment of a suff ic ient number of macrophages to ki l l  large numbers
of tumor cells. Adoptive cellular therapy, in which monocytes can be isolated from the
peripheral  blood with large numbers, and are administered to the pat ients after
activation in vitro, might provide a solution. lt will, however, require extensive
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additionar studies to achieve an immunotherapeutic treatment bas,ed. on macrophage
,ïJ,,"J""ut" 
activation that significanirv àoà.'to currenity oËàiiËo cnemotherapeuric
I
(
t
c
c
c
o
k
Zl
o
n i
c(
D
kt
or
ai
fa
dc
Or
VE
m(
WA
ber
cyt
gel
uit
the
cyt(
128
